What the term "injectable peptides" denotes
For laboratory research only. Catalogue products are not intended for administration to humans or animals.
In the literature and in research-supply catalogues, "injectable" is the name of a pharmaceutical form. It states that the compound is supplied packaged as a lyophilised powder in a vial. It is a classification label, like "powder" or "solution", and exists so one entry can be told apart from another.
What the term does not denote
It does not denote approval, suitability or purpose. A compound recorded in that form is not an approved medicine because it carries the label, and the label says nothing about whether a compound holds a marketing authorisation. Catalogue compounds are supplied as reference material for laboratory research.
What a marketing authorisation is, and why research material has none
A marketing authorisation is not granted to a chemical substance. It is granted to one specific medicinal product, which has its own holder, its own form and a full quality and manufacturing dossier that a regulator assesses before approval.
In the European Medicines Agency register, the first medicine with semaglutide as its active substance received an authorisation valid throughout the European Union on 8 February 2018, held by Novo Nordisk A/S. For tirzepatide the corresponding date is 15 September 2022, held by Eli Lilly Nederland B.V.
Research material goes through no such assessment and holds no authorisation. It does not become a medicine because it is described with the same form or name as an authorised medicine.
The same term in another setting
In Greek, the phrase "injectable peptides" is often used for something different: aesthetic facial practices carried out in a clinical setting by a health professional.
That is a different product category and a different regulatory framework from a research catalogue. This page does not describe them and does not judge them. It mentions them because one phrase leads to two separate things.
The term in the Avenor catalogue
The catalogue groups compounds by research field, and the form is stated in each entry. The compound library lists each compound's alternative names, class and research-status label.
What RUO means
RUO stands for Research Use Only. The label states that the material is intended for laboratory research and not for diagnostic or therapeutic use. FOR RESEARCH PURPOSES ONLY.
What remains open
This page explains what a catalogue term means and stops there. It does not answer what anyone does with a compound, nor does it compare forms with one another. For many catalogue compounds, human research is at an early stage and the studies are small, and several sit in a transitional regulatory status with a final decision pending.
Something more basic also remains open: a form label says nothing about the identity or purity of a batch. Those are judged batch by batch, from the certificate of analysis.
Frequently asked questions
Is this the same as the peptides in face creams?
No. In cosmetics, a peptide is an ingredient of a product that falls under Regulation (EC) No 1223/2009 on cosmetic products. In a research catalogue, "injectable" describes the form of the material and concerns laboratory research.
Does a research-use peptide hold a marketing authorisation?
No. A marketing authorisation is granted by a regulator to a specific medicinal product, after it assesses the dossier. Research material is not such a product and has not been through that process.
What does "lyophilised powder" mean?
It is powder produced by freeze-drying, a preparation method that removes water from a material. The term describes the form of the material and says nothing about its regulatory status.
Sources
- European Medicines Agency, EPAR assessment page for the [first medicine with semaglutide as its active substance](https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic)
- European Medicines Agency, EPAR assessment page for a [medicine with tirzepatide as its active substance](https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro)
- [Regulation (EC) No 1223/2009 on cosmetic products](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32009R1223), EUR-Lex
Note
Last reviewed: 6 November 2026. The text describes catalogue terminology and published literature. It is not medical advice and does not describe use.